SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NeuBase Therapeutics, Inc. (NBSE) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 28/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NBSE
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-21.08
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-120.86 |
$0.00 |
$-5.65M |
- |
| 2014 |
$-164.95 |
$0.00 |
$-9.13M |
- |
| 2015 |
$-214.02 |
$0.00 |
$-15.2M |
- |
| 2016 |
$-328.76 |
$0.00 |
$-25.77M |
- |
| 2017 |
$-212.74 |
$0.00 |
$-23.81M |
- |
| 2018 |
$-93.57 |
$0.00 |
$-13.24M |
- |
| 2019 |
$-65.49 |
$0.00 |
$-27.09M |
- |
| 2020 |
$-17.60 |
$0.00 |
$-17.26M |
- |
| 2021 |
$-18.80 |
$0.00 |
$-25.67M |
- |
| 2022 |
$-21.08 |
$0.00 |
$-34.23M |
- |
